Advances in immunotherapy for prostate cancer

Advances in Cancer Research

Volumn 87, Issue , 2003, Pages 159-194

  Markiewicz, Mary A ^a   Kast, W Martin ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CELL PROTEIN; COMPLEMENTARY DNA; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; FLT3 LIGAND; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; MONOCLONAL ANTIBODY; ONCOPROTEIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECOMBINANT VACCINE; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS VACCINE; YTTRIUM 90;

ACTIVE IMMUNIZATION; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETIC ENGINEERING; HUMAN; IMMUNOTHERAPY; MALE; MALE GENITAL TRACT CANCER; MOUSE; NONHUMAN; ONCOGENE NEU; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; RAT; REVIEW; TUMOR CELL; TUMOR GROWTH; VACCINATION; VIRAL GENE THERAPY;

EID: 0037289276     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(03)87200-7     Document Type: Review

References (153)

1. Ablin, R. J., Soanes, W. A., Bronson, P., and Witebsky, E. (1970). Precipitating antigens of the normal human prostate. J. Reprod. Fertil. 22, 573-574.
2. Afar, D. E., Vivanco, I., Hubert, R. S., Kuo, J., Chen, E., Saffran, D. C., Raitano, A. B., and Jakobovits, A. (2001). Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 61, 1686-1692.
3. Agus, D. B., Scher, H. I., Higgins, B., Fox, W. D., Heller, G., Fazzari, M., Cordon-Cardo, C., and Golde, D. W. (1999). Response of prostate cancer to anti-HER-2/neu antibody in androgen-dependent and independent human xenograft models. Cancer Res. 59, 4761-4764.
4. Alexander, R. B., Brady, E, Leffell, M. S., Tsai, V., and Celis, E. (1998). Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 51, 150-157.
5. Angiolillo, A. L., Sgadari, C., and Tosato, G. (1996). A role for interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann. N.Y. Acad. Sci. 795, 158-167.
6. Awwad, M., and North, R. J. (1989). Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: A consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res. 49, 1649-1654.
7. Bander, N. H., Yao, D., Liu, H., Chen, Y. T., Steiner, M., Zuccaro, W., and Moy, P. (1997). MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33, 233-239.
8. Blades, R. A., Keating, P. J., McWilliam, L. J., George, N. J., and Stern, P. L. (1995). Loss of HLA class I expression in prostate cancer: Implications for immunotherapy. Urology 46, 681-686; discussion 686-687.
9. Brasel, K., McKenna, H. J., Morrissey, P. J., Charrier, K., Morris, A. E., Lee, C. C., Williams, D. E., and Lyman, S. D. (1996). Hematologic effects of flt3 ligand in vivo in mice. Blood 88, 2004-2012.
10. Brinkmann, U., Vasmatzis, G., Lee, B., Yerushalmi, N., Essand, M., and Pastan, I. (1998). PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc. Natl. Acad. Sci. USA 95, 10757-10762.
11. Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R. L., Padley, D. J., Peshwa, M. V., Pitot, H. C., Richardson, R. L., Smits, B. J., Sopapan, P., Strang, G., Valone, F. H., and Vuk-Pavlovic, S. (2000). Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175-2182.
12. Carson, W. E., Fehniger, T. A., Haldar, S., Eckhert, K., Lindemann, M. J., Lai, C. F., Croce, C. M., Baumann, H., and Caligiuri, M. A. (1997). A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99, 937-943.
13. Cesano, A., Visonneau, S., and Santoli, D. (1998). TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice. Anticancer Res. 18, 2289-2295.
14. Chang, S. S., Reuter, V. E., Heston, W. D., Bander, N. H., Grauer, L. S., and Gaudin, P. B. (1999). Five different anti -prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192-3198.
15. Chen, M. E., Lin, S. H., Chung, L. W., and Sikes, R. A. (1998). Isolation and characterization of PAGE-1 and GAGE-7: New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J. Biol. Chem. 273, 17618-17625.
16. Ciavarra, R. P., Somers, K. D., Brown, R. R., Glass, W. F., Consolvo, P. J., Wright, G. L., and Schellhammer, P. F. (2000). Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res. 60, 2081-2084.
17. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. (1997). In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89, 293-300.
18. Correale, P., Walmsley, K., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. (1998). Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol. 161, 3186-3194.
19. Coughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J. E., Lui, L., Liao, E, Farber, M., Pestka, S., Trinchieri, G., and Lee, W. M. (1998). Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9, 25-34.
20. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med. 5, 280-285.
21. Deb, N., Goris, M., Trisler, K., Fowler, S., Saal, J., Ning, S., Becker, M., Marquez, C., and Knox, S. (1996). Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin. Cancer Res. 2, 1289-1297.
22. Deguchi, T., Chu, T. M., Leong, S. S., Horoszewicz, J. S., and Lee, C. L. (1986). Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. Cancer Res. 46, 3751-3755.
23. Deguchi, T., Chu, T. M., Leong, S. S., Horozsewicz, J. S., and Lee, C. L. (1987). Potential therapeutic effect of adriamycin-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. J. Urol. 137, 353-358.
24. Disis, M. L., and Cheever, M. A. (1997). HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71, 343-371.
25. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
26. Dreicer, R., See, W. A., and Klein, E. A. (2001). Phase II trial of GM-CSF in advanced prostate cancer. Invest. New Drugs 19, 261-265.
27. Earp, H. S., Dawson, T. L., Li, X., and Yu, H. (1995). Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 35, 115-132.
28. Eder, J. P., Kantoff, P. W., Roper, K., Xu, G. X., Bubley, G. J., Boyden, J., Gritz, L., Mazzara, G., Oh, W. K., Arlen, P., Tsang, K. Y., Panicali, D., Schlom, J., and Kufe, D. W. (2000). A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632-1638.
29. Fehniger, T. A., Yu, H., Cooper, M. A., Suzuki, K., Shah, M. H., and Caligiuri, M. A. (2000). Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J. Immunol. 164, 1643-1647.
30. Feltcamp, M. C., Smits, H. L., Vierboom, M. P., Minnaar, R. P., de Jongh, B. M., Drijshout, J. W., ter Schegget, J., Melief, C. J., and Kast, W. M. (1993). Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249.
31. Finn, O. J., Jerome, K. R., Henderson, R. A., Pecher, G., Domenech, N., Magarian-Blander, J., and Barratt-Boyes, S. M. (1995). MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61-89.
32. Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C., and Engleman, E. G. (2001). Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 167, 7150-7156.
33. Fong, L., Ruegg, C. L., Brockstedt, D., Engleman, E. G., and Laus, R. (1997). Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. J. Immunol. 159, 3113-3117.
34. Fuerst, J., Fiebiger, E., Jungwirth, A., Mack, D., Talwar, P. G., Frick, J., and Rovan, E. (1997). Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines. Prostate 32, 77-84.
35. Gagandeep, S., Brew, R., Green, B., Christmas, S. E., Klatzmann, D., Poston, G. J., and Kinsella, A. R. (1996). Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect." Cancer Gene Ther. 3, 83-88.
36. Giri, D. K., Jayaraman, S., Neelaram, G. S., Jayashankar, R., and Talwar, G. P. (1991). Prostatic hypoplasia in bonnet monkeys following active immunization with semisynthetic anti-LHRH vaccine. Exp. Mol. Pathol. 54, 255-264.
37. Gong, M. C., Latouche, J. B., Krause, A., Heston, W. D., Bander, N. H., and Sadelain, M. (1999). Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123-127.
38. Granziero, L., Krajewski, S., Farness, P., Yuan, L., Courtney, M. K., Jackson, M. R., Peterson, P. A., and Vitiello, A. (1999). Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur. J. Immunol. 29, 1127-1138.
39. Greenberg, N. M., DeMayo, E, Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., and Rosen, J. M. (1995). Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92, 3439-3443.
40. Gu, Z., Shintaku, P., Yamashiro, J., Said, J., and Reiter, R. (1999). Monoclonal antibodies against PSCA detect high levels of PSCA expression in prostate cancer bone metastases. J. Urol. 161(suppl.), 126.
41. Guinan, P., Crispen, R., Baumgartner, G., Rao, R., Totonchi, E., Ablin, R., and John, T. (1979). Adjuvant immunotherapy with bacillus Calmette-Guerin in prostatic cancer. Urology 14, 561-565.
42. Guinan, P. D., John, T., Baumgartner, G., Sundar, B., and Ablin, R. J. (1982). Adjuvant immunotherapy (BCG) in stage D prostate cancer. Am. J. Clin. Oncol. 5, 65-68.
43. Gutman, E., Sproul, E., and Gutman, A. (1936). Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am. J. Cancer 28, 485.
44. Hall, S. J., Sanford, M. A., Atkinson, G., and Chen, S. H. (1998). Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 58, 3221-3225.
45. Hara, M., Inorre, T., and Fukuyama, T. (1971). Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Jap. J. Legal Med. 25, 322-324.
46. Hassan, W., Sanford, M. A., Woo, S. L., Chen, S. H., and Hall, S. J. (2000). Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. World J. Urol. 18, 130-135.
47. Hautmann, S., Huland, E., Wullbrand, A., Friedrich, M., and Huland, H. (2000). Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps. Anticancer Res. 20, 4495-4498.
48. Hautmann, S. H., Huland, E., and Huland, H. (1999). Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res. 19, 2661-2663.
49. Healy, C. G., Simons, J. W., Carducci, M. A., DeWeese, T. L., Bartkowski, M., Tong, K. P., and Bolton, W. E. (1998). Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32, 109-119.
50. Heinzer, H., Huland, E., and Huland, H. (2001). Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J. Urol. 19, 111-119.
51. Henriksson, R., Widmark, A., Bergh, A., and Damber, J. E. (1992). Interleukin-2-induced growth inhibition of prostatic adenocarcinoma (Dunning R3327) in rats. Urol. Res. 20, 189-191.
52. Herman, J. R., Adler, H. L., Aguilar-Cordova, E., Rojas-Martinez, A., Woo, S., Timme, T. L., Wheeler, T. M., Thompson, T. C., and Scardino, P. T. (1999). In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum. Gene Ther. 10, 1239-1249.
53. Herr, H. W. (1980). Suppressor cells in immunodepressed bladder and prostate cancer patients. J. Urol. 123, 635-639.
54. Hodge, J. W., Schlom, J., Donohue, S. J., Tomaszewski, J. E., Wheeler, C. W., Levine, B. S., Gritz, L., Panicali, D., and Kantor, J. A. (1995). A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate. Int. J. Cancer 63, 231-237.
55. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. (1987). Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 7, 927-935.
56. Hrouda, D., Baban, B., Dunsmuir, W. D., Kirby, R. S., and Dalgleish, A. G. (1998a). Immunotherapy of advanced prostate cancer: A phase I/II trial using Mycobacterium vaccae (SRL172). Br. J. Urol. 82, 568-573.
57. Hrouda, D., Souberbielle, B. E., Kayaga, J., Corbishley, C. M., Kirby, R. S., and Dalgleish, A. G. (1998b). Mycobacterium vaccae (SRL172): A potential immunological adjuvant evaluated in rat prostate cancer. Br. J. Urol. 82, 870-876.
58. Huang, A. Y., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I. (1996). Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183, 769-776.
59. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
60. Hubert, R. S., Vivanco, I., Chen, E., Rastegar, S., Leong, K., Mitchell, S. C., Madraswala, R., Zhou, Y., Kuo, J., Raitano, A. B., Jakobovits, A., Saffran, D. C., and Afar, D. E. (1999). STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl. Acad. Sci. USA 96, 14523-14528.
61. Huland, E., Heinzer, H., Mir, T. S., and Huland, H. (1997). Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience. Cancer J. Sci. Am. 3(Suppl. 1), S98-S105.
62. Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B., and Allison, J. P. (2000). Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60, 2444-2448.
63. Isaacs, J. T., Heston, W. D., Weissman, R. M., and Coffey, D. S. (1978). Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res. 38, 4353-4359.
64. Isaacs, J. T., Isaacs, W. B., Feitz, W. F., and Scheres, J. (1986). Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9, 261-281.
65. Israeli, R. S., Miller, W. H. Jr., Su, S. L., Samadi, D. S., Powell, C. T., Heston, W. D., Wise, G. J., and Fair, W. R. (1995). Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J. Urol. 153, 573-577.
66. Jacobs, E. L., and Haskell, C. M. (1991). Clinical use of tumor markers in oncology. Curr. Probl. Cancer 15, 299-360.
67. Jayashankar, R., Chaudhuri, M. K., Singh, O., Alam, A., and Talwar, G. P. (1989). Semisynthetic anti-LHRH vaccine causing atrophy of the prostate. Prostate 14, 3-11.
68. Katzenwadel, A., Schleer, H., Gierschner, D., Wetterauer, U., and Elsasser-Beile, U. (2000). Construction and in vivo evaluation of an anti-PSA × anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res. 20, 1551-1555.
69. Kawakami, M., and Nakayama, J. (1997). Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57, 2321-2324.
70. Kim, J. J., Trivedi, N. N., Wilson, D. M., Mahalingam, S., Morrison, L., Tsai, A., Chattergoon, M. A., Dang, K., Patel, M., Ahn, L., Boyer, J. D., Chalian, A. A., Schoemaker, H., Kieber-Emmons, T., Agadjanyan, M. A., Weiner, D. B., and Shoemaker, H. (1998). Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 17, 3125-3135.
71. Kim, J. J., Yang, J. S., Nottingham, L. K., Tang, W., Dang, K., Manson, K. H., Wyand, M. S., Wilson, D. M., and Weiner, D. B. (2001). Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 20, 4497-4506.
72. Klein, G., and Boon, T. (1993). Tumor immunology: Present perspectives. Curr. Opin. Immunol. 5, 687-692.
73. Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., and Sawyers, C. L. (1997). Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Med. 3, 402-408.
74. Kocheril, S. V., Grignon, D. J., Wang, C. Y., Maughan, R. L., Montecillo, E. J., Talati, B., Tekyi-Mensah, S., Pontes, J., and Hillman, G. G. (1999). Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model. Cancer Detect. Prev. 23, 408-416.
75. Kramer, G., Steiner, G. E., Sokol, P., Handisurya, A., Klingler, H. C., Maier, U., Foldy, M., and Marberger, M. (2001). Local intratumoral tumor necrosis factor-α and systemic IFN-α in patients with locally advanced prostate cancer. J. Interferon Cytokine Res. 21, 475-484.
76. Kuhn, E. J., Kurnot, R. A., Sesterhenn, I. A., Chang, E. H., and Moul, J. W. (1993). Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol. 150, 1427- 1433.
77. Kuniyasu, H., Wataru, Y., Pettaway, C. A., Yano, S., Oue, N., Tahara, E., and Fidler, I. J. (2001). Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. Prostate 49, 19-29.
78. Kwon, E. D., Foster, B. A., Hurwitz, A. A., Madias, C., Allison, J. P., Greenberg, N. M., and Burg, M. B. (1999). Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl. Acad. Sci. USA 96, 15074-15079.
79. Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., and Allison, J. P. (1997). Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94, 8099-8103.
80. Lam, K. W., Li, C. Y., Yam, L. T., Sun, T., Lee, G., and Ziesmer, S. (1989). Improved immuno-histochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 15, 13-21.
81. Lee, C. T., and Oesterling, J. E. (1995). Diagnostic markers of prostate cancer: Utility of prostate-specific antigen in diagnosis and staging. Semin. Surg. Oncol. 11, 23-35.
82. Lilja, H. (1985). A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899-1903.
83. Lin, B., Ferguson, C., White, J. T., Wang, S., Vessella, R., True, L. D., Hood, L., and Nelson, P. S. (1999). Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180-4184.
84. Lodge, P. A., Jones, L. A., Bader, R. A., Murphy, G. P., and Salgaller, M. L. (2000). Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res. 60, 829-833.
85. Maffezzini, M., Simonato, A., and Fortis, C. (1996). Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha -interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 28, 282-286.
86. Mandelboim, O., Vadai, E., Fridkin, M., Katz-Hillel, A., Feldman, M., Berke, G., and Eisenbach, L. (1995). Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nature Med. 1, 1179-1183.
87. Mao, M., Yu, M., Tong, J. H., Ye, J., Zhu, J., Huang, Q. H., Fu, G., Yu, L., Zhao, S. Y., Waxman, S., Lanotte, M., Wang, Z. Y., Tan, J. Z., Chan, S. J., and Chen, Z. (1996). RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc. Natl. Acad. Sci. USA 93, 5910-5914.
88. Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., and McKenna, H. J. (1996). Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953-1962.
89. Marchand, M., Weynants, P., Rankin, E., Arienti, E, Belli, E, Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humbler, Y., et al. (1995). Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883-885.
90. Mark, H. F., Feldman, D., Das, S., Kye, H., Mark, S., Sun, C. L., and Samy, M. (1999), Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp. Mol. Pathol. 66, 170-178.
91. Markiewicz, M. A., and Gajewski, T. F. (1999). The immune system as anti-tumor sentinel: Molecular requirements for an anti-tumor immune response. Crit. Rev. Oncog. 10, 247-260.
92. McDevitt, M. R., Barendswaard, E., Ma, D., Lai, L., Curcio, M. J., Sgouros, G., Ballangrud, A. M., Yang, W. H., Finn, R. D., Pellegrini, V., Geerlings, M. W., Jr., Lee, M., Brechbiel, M. W., Bander, N. H., Cordon-Cardo, C., and Scheinberg, D. A. (2000). An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60, 6095-6100.
93. Mellon, K., Thompson, S., Charlton, R. G., Marsh, C., Robinson, M., Lane, D. P., Harris, A. L., Horne, C. H., and Neal, D. E. (1992). p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol. 147, 496-499.
94. Mercader, M., Bodner, B. K., Moser, M. T., Kwon, P. S., Park, E. S. Y., Manecke, R. G., Ellis, T. M., Wojcik, E. M., Yang, D., Flanigan, R. C., Waters, W. B., Kast, W. M., and Kwon, E. D. (2001). T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. USA 98, 14565-14570.
95. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Schlom, J., Russell, C. D., Liu, T., and LoBuglio, A. F. (1994). Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucleic Med. 35, 1017-1022.
96. Meredith, R. F., Khazaeli, M. B., Macey, D. J., Grizzle, W. E., Mayo, M., Schlom, J., Russell, C. D., and LoBuglio, A. F. (1999). Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5, 3254s-3258s.
97. Mincheff, M., Tchakarov, S., Zoubak, S., Loukinov, D., Botev, C., Altankova, I., Georgiev, G., Petrov, S., and Meryman, H. T. (2000). Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur. Urol. 38, 208-217.
98. Morris, M. J., Reuter, V. E., Kelly, W. K., Slovin, S. E, Kenneson, K., Verbel, D., Osman, I., and Scher, H. I. (2002). HER-2 profiling and targeting in prostate carcinoma. Cancer 94, 980-986.
99. Mrozek, E., Anderson, P., and Caligiuri, M. A. (1996). Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 87, 2632-2640.
100. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. (1996). Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29, 371-380.
101. Nakajima, Y., Dellipizzi, A., Mallouh, C., and Ferreri, N. R. (1995). Effect of tumor necrosis factor-α and interferon-γ on the growth of human prostate cancer cell lines. Urol. Res. 23, 205-210.
102. Nelson, P. S., Gan, L., Ferguson, C., Moss, P., Gelinas, R., Hood, L., and Wang, K. (1999). Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc. Natl. Acad. Sci. USA 96, 3114-3119.
103. Oesterling, J. E. (1991). Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145, 907-923.
104. Ogasawara, K., Hida, S., Azimi, N., Tagaya, Y., Sato, T., Yokochi-Fukuda, T., Waldmann, T. A., Taniguchi, T., and Taki, S. (1998). Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391, 700-703.
105. Ohteki, T., Yoshida, H., Matsuyama, T., Duncan, G. S., Mak, T. W., and Ohashi, P. S. (1998). The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells. J. Exp. Med. 187, 967-972.
106. Papsidero, L. D., Wang, M. C., Valenzuela, L. A., Murphy, G. P., and Chu, T. M. (1980). A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40, 2428-2432.
107. Pirtskhalaishvili, G., and Nelson, J. B. (2000). Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 44, 77-87.
108. Polascik, T. J., Oesterling, J. E., and Partin, A. W. (1999). Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J. Urol. 162, 293-306.
109. Pollard, M., and Luckert, P. H. (1994). The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex of L-W rats. Anticancer Res. 14, 901-903.
110. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953-962.
111. Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., Wahl, M., Nisitani, S., Yamashiro, J., Le Beau, M. M., Loda, M., and Witte, O. N. (1998). Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 95, 1735-1740.
112. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., and Greenberg, P. D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-241.
113. Rini, B. I., and Small, E. J. (2001). Immunotherapy for prostate cancer. Curr. Oncol. Rep. 3, 418-423.
114. Rivas, C. I., Vera, J. C., Delgado-Lopez, E, Heaney, M. L., Guaiquil, V. H., Zhang, R. H., Scher, H. I., Concha, II, Nualart, F., Cordon-Cardo, C., and Golde, D. W. (1998). Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. Blood 91, 1037-1043.
115. Ross, S., Liu, V., Abulafia, R., Hogan, C., and Osband, M. (1993). Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): Results from a pilot study Biotechnol. Ther. 4, 197-211.
116. Rovan, E., Fiebiger, E., Kalla, N. R., Talwar, G. P., Aulitzky, W., and Frick, J. (1992). Effect of active immunization to luteinizing-hormone-releasing hormone on the fertility and histoarchitecture of the reproductive organs of male rat. Urol. Res. 20, 323-334.
117. Saffran, D. C., Raitano, A. B., Hubert, R. S., Witte, O. N., Reiter, R. E., and Jakobovits, A. (2001). Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl. Acad. Sci. USA 98, 2658-2663.
118. Saffran, D. C., Reiter, R. E., Jakobovits, A., and Witte, O. N. (1999). Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev. 18, 437-449.
119. Salgaller, M. L. (2000). Prostate cancer immunotherapy at the dawn of the new millennium. Expert Opin. Invest. Drugs 9, 1217-1229.
120. Salgaller, M. L., Lodge, P. A., McLean, J. G., Tjoa, B. A., Loftus, D. J., Ragde, H., Kenny, G. M., Rogers, M., Boynton, A. L., and Murphy, G. P. (1998). Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35, 144-151.
121. Sanda, M. G. (1997). Biological principles and clinical development of prostate cancer gene therapy. Semin. Urol. Oncol. 15, 43-55.
122. Sanda, M. G., Ayyagari, S. R., Jaffee, E. M., Epstein, J. I., Clift, S. L., Cohen, L. K., Dranoff, G., Pardoll, D. M., Mulligan, R. C., and Simons, J. W. (1994). Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151, 622-628.
123. Sanda, M. G., Smith, D. C., Charles, L. G., Hwang, C., Pienta, K. J., Schlom, J., Milenic, D., Panicali, D., and Montie, J. E. (1999). Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 53, 260-266.
124. Sherwood, E. R., Ford, T. R., C., L., and Kozlowski, J. M. (1990). Therapeutic efficacy of recombinant tumor necrosis factor-α in an experimental model of human prostatic carcinoma. J. Biol. Response Modif. 9, 44-52.
125. Simms, M. S., Scholfield, D. P., Jacobs, E. L., Michaeli, D., Broome, P., Humphreys, J. E., and Bishop, M. C. (2000). Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br. J. Cancer 83, 443-446.
126. Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Lim, M., Weber, C. E., Baccala, A. A., Goemann, M. A., Clift, S. M., Ando, D. G., Levitsky, H. I., Cohen, L. K., Sanda, M. G., Mulligan, R. C., Partin, A. W., Carter, H. B., Piantadosi, S., Marshall, F. F., and Nelson, W. G. (1999). Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160-5168.
127. Sinha, A. A., Quast, B. J., Reddy, P. K., Elson, M. K., and Wilson, M. J. (1999). Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2′-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anticancer Res. 19, 893-902.
128. Sinha, A. A., Quast, B. J., Wilson, M. J., Reddy, P. K., Fernandes, E. T., Ewing, S. L., and Gleason, D. F. (1998). Immunocytochemical localization of an immunoconjugate (antibody IgG against prostatic acid phosphatase conjugated to 5- fluoro-2′-deoxyuridine) in human prostate tumors. Anticancer Res. 18, 1385-1392.
129. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
130. Slovin, S. F. (2001). Vaccines as treatment strategies for relapsed prostate cancer: Approaches for induction of immunity. Hematol. Oncol. Clin. North Am. 15, 477-496.
131. Slovin, S. F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova, M., Bornmann, W. G., Fazzari, M., Dantis, L., Olkiewicz, K., Lloyd, K. O., Livingston, P. O., Danishefsky, S. J., and Scher, H. I. (1999). Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA 96, 5710-5715.
132. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., and Valone, F. H. (2000). Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903.
133. Solin, T., Kontturi, M., Pohlmann, R., and Vihko, P. (1990). Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses. Biochim. Biophys. Acta 1048, 72-77.
134. Srivastava, P. K., Udono, H., Blachere, N. E., and Zihai, L. (1994). Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39, 93-98.
135. Stravodimos, K., Constantinides, C., Manousakas, T., Pavlaki, C., Pantazopoulos, D., Giannopoulos, A., and Dimopoulos, C. (2000). Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: Divergent correlation with clinicopathological parameters. Anticancer Res. 20, 3823-3828.
136. Suto, R., and Srivastava, P. K. (1995). A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269, 1585-1588.
137. Suzuki, K., Nakazato, H., Matsui, H., Hasumi, M., Shibata, Y., Ito, K., Fukabori, Y., Kurokawa, K., and Yamanaka, H. (2001). NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: Immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J. Leukocyte Biol. 69, 531-537.
138. Tanimoto, H., Yan, Y., Clarke, J., Korourian, S., Shigemasa, K., Parmley, T. H., Parham, G. P., and O'Brien, T. J. (1997). Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 57, 2884-2887.
139. Terasawa, H., Tsang, K. Y., Gulley, J., Arlen, P., and Schlom, J. (2002). Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin. Cancer Res. 8, 41-53.
140. Tjoa, B., Boynton, A., Kenny, G., Ragde, H., Misrock, S. L., and Murphy, G. (1996). Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate. 28, 65-69.
141. Tjoa, B. A., and Murphy, G. P. (2000). Progress in active specific immunotherapy of prostate cancer. Semin. Surg. Oncol. 18, 80-87.
142. Tjoa, B. A., Simmons, S. J., Elgamal, A., Rogers, M., Ragde, H., Kenny, G. M., Troychak, M. J., Boynton, A. L., and Murphy, G. P. (1999). Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40, 125-129.
143. Triest, J. A., Grignon, D. J., Cher, M. L., Kocheril, S. V., Montecillo, E. J., Talati, B., Tekyi-Mensah, S., Pontes, J. E., and Hillman, G. G. (1998). Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model. Clin. Cancer Res. 4, 2009-2014.
144. Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., and Boon, T. (1995). A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182, 689-698.
145. van Moorselaar, R. J., Hendriks, B. T., van Stratum, P., van der Meide, P. H., Debruyne, F. M., and Schalken, J. A. (1991). Synergistic antitumor effects of rat gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumors. Cancer Res. 51, 2329-2334.
146. Wadler, S. (1991). The role of interferons in the treatment of solid tumors. Cancer 70, 949-958.
147. Ware, J. L., Maygarden, S. J., Koontz, W. W., Jr., and Storm, S. C. (1991). Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum. Pathol. 22, 254-258.
148. Wei, C., Willis, R. A., Tilton, B. R., Looney, R. J., Lord, E. M., Barth, R. K., and Frelinger, J. G. (1997). Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy. Proc. Natl. Acad. Sci. USA 94, 6369-6374.
149. Yang, D., Holt, G. E., Velders, M. P., Kwon, E. D., and Kast, W. M. (2001). Murine Steap, Psca, and Psma: Prostate-specific cell surface antigens highly expressed in prostate cancer of TRAMP mice. Cancer Res. 61, 5857.
150. Yedavelli, S. P., Guo, L., Daou, M. E., Srivastava, P. K., Mittelman, A., and Tiwari, R. K. (1999). Preventive and therapeutic effect of tumor derived heat shock protein, gp96 in an experimental prostate cancer model. Int. J. Mol. Med. 4, 243-248.
151. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang, C. (1999). From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 96, 5458-5463.
152. Yousef, G. M., Obiezu, C. V., Luo, L. Y., Black, M. H., and Diamandis, E. P. (1999). Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res. 59, 4252-4256.
153. Zhang, S., Graeber, L. A., Helling, F., Ragupathi, G., Adluri, S., Lloyd, K. O., and Livingston, P. O. (1996). Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res. 56, 3315-3319.